Introduction
Significant effort has been expended in developing com-pounds that inferfere with human immunodeficiency Virus type 1 (HIV-1) replication (Mitsuya et aI., 1991) . Development of effective treatments will necessitate suppression or elimination of virus replication by virus producing cells, thus preventing the spread of Virus or fusion of infected cells with uninfected cells. A variety of assays for acute infections have been used for discovering compounds to treat HIV-1 infection. These assays require the measurement of virus or virus gene products by fluorescence, formation of foci or synctia, reverse transcriptase (RT) activity, p24 antigen levels, viral RNA, and colorimetric assays (Schinazi, 1988) . More recently, the focus has shifted to antiviral assays that could lead to discovering compounds that prevent or reduce virus production in chronically infected cells. Whereas success has been achieved at identifying several nucleoside and nonnucleoside analogues as inhibitors of acute infection, such as AZT and TIBO analogues, few compounds selectively inhibit chronically infected cells (McGrath et aI., 1990; Pauwels et al., 1990; Hargrave et al., 1991; Hsu et al., 1991; Lee-Huang et aI., 1991; Martin, 1992) .
HIV infection of lymphocytes leads to acute cell death, chronic infection, and latent infection. It is assumed that, in a patient infected with HIV, these cells are present to a different extent depending on the patient's disease stage. Current information indicates that the in vivo reservoir for HJV-1 is a CD4+ population of cells . Because surface CD4 down modulates active viral replication (Butera et al., 1991) and the disparate frequency of cells containing viral DNA (Psallidopoulos et aI., 1989) and those expressing viral RNA at detectable levels (Harper et al., 1986) , this CD4+ reservoir most likely represents a major population of latently-infected cells. Although the emphasis has been on the development of effective anti-HIV agents in acute and chronic infection cell culture models, a modest effort has gone into cell culture models, including the U1 cell system, that can be useful in predicting if a compound can prevent the reactivation of latent virus (Folks et al., 1987; Legrand-Pels et aI., 1990) . Compounds capable of preventing HIV-1 activation could potentially prolong the period of clinical latency in HIV-1 positive individuals prior to the onset of AIDS. The development of a reliable and simple system for evaluating compounds that could prevent activation of latent HIV would allow us to devise new therapies for this infection. The eventual use of such therapies would be to combine :J cr u.. them with drugs that are effective against acute and chronic infections. The OM-10.1 cell line is a chronically infected clone derived from an acute HIV-1 infection of HL-60 cells and harbouring a single provirus (Butera et al., 1991) . Unlike other chronically-infected cell lines, OM-10.1 cells remain CD4+ until HIV-1 activation with tumour necrosis factor-a (TNF-a) and then undergo a rapid and reliable loss of surface CD4 concomitant with increased viral expression. Furthermore, when the activating stimulus is removed from OM-10.1, cultures, HIV-1 returns to a state of latency, and surface CD4 reappears. Therefore, the OM-10.1 cell line provides a novel system to investigate HIV-1 latency and activation. A variety of compounds known to have antiviral properties against either acutely or chronically infected cells were evaluated for their ability to inhibit activation of HIV expression in these cells. Some of these compounds are already at different stages of clinical development in humans, whereas others have been described inhibiting HIV-1 replication in culture. We also examined the effect of several compounds that interact with biochemical pathways that may interfere with or enhance the reactivation process. The inhibitory activity of the tested compounds was evaluated by measuring CD4 cellular expression and the presence of supernatant viral RT activity. Of the 58 compounds tested, only 3'-fluoro-3'-deoxythymidine (FL1), interferon 'Y, 7-chloro-5-(2-pyrryl)-3H-1 A-benzodiazepin-2(H}-one (Ro 5-3335), and desferrioxamine modestly inhibited the activation of HIV-1. Since the prevention of HIV-1 reactivation with FLT may involve an unrecognized metabolite of FLTin promyelocytes, we also determined the intracellular metabolism of this nucleoside, and explored the mechanism by which FLT inhibits virus reactivation by attempting to reverse the observed effect with thymidine.
Results
The 58 compounds that were initially tested at 1, 10, and 100 f.LM in the OM-10.1 system are listed in Table 1 . In this test system FLT, interferon 'Y, Ro 5-3335, and desferrioxamine, repeatedly showed inhibition of HIV activation as measured by CD4 receptor loss. None of the other compounds or nucleosides evaluated inhibited HIV activation, including AlT, when tested up to 100 f.LM. Figure 1a demonstrates the pattern of CD4 expression by normal OM-10.1 cells without antiviral compound or TNF-a induction, which indicates that 85% of the cells are CD4+. Figure 1b indicates the percentage of CD4+ cells 24 h after TNF-a induction, and only about 10% of the cells remain positive. AlT at concentrations up to 40 f.LM showed no ability to block HIV activation ( Fig. 1c) , while FLTat 40 f.LM resulted in 28%· of the cells remaining CD4+. The difference between the TNF-a treated and FLT plus TNF-a Table 1 . Compounds evaluated in the OM-1 0.1 System. Italicized bold compound showed significant activity in the OM-10.1 system at 40-100 p.m. Chu et al., 1989 Chu et al., 1988 Eriksson et al., 1989 Chu et al., 1989 Chu et al., 1989 Dr. D. Liotta (Atlanta, GA) Dr. D. Liotta (Atlanta, GA) treated culture can be seen in Figure 1d ; i.e., there are more CD4+ cells, and there is a discernable shift of the histogram towards positivity in the CD4 negative cells from the FLT treated culture. With FLT, the percentage of CD4+ cells increased with increasing concentration of the drug. However, complete prevention of HIV-1 activation and protection of CD4 positivity with FLT was not possible even when this nucleoside was tested up to 100 fLM. Interestingly, related compounds containing the 3'-fluoro function on the sugar moiety of the pyrimidine nucleosides were ineffective. These fluorinated compounds included the uracil, cytidine, and 5-methylcytidine analogues of FLT (Table 1) . Dilutions (1, 2.5, 5, 10, 20 and 40 fLM) of FLT were again tested with and without thymidine for anti-HIV activity by measuring CD4+ cells and RT activity in the cell culture supernatant. The results are summarized in Table 2 . The non-TNF-u induced, non-antiviral control had 83% CD4+ cells and an RT activity of about 1000 c.p.m., and the TNF-u induced non-antiviral control had 10% CD4+ cells and RT activity of 26000 c.p.m. All FLT dilutions between 1.0 fLM and 40.0 fLM inhibited RT activity and CD410ss with or without 100 fLM thymidine. FLT at 0.1 fLM and thymidine alone at 100 fLM did not inhibit HIVactivation. Interestingly, when 40 fLM of FLT was tested with 20, 10, or 5 U mr' of TNF-u the inhibition increased about 25% (data not shown).
The four drugs originally found to have activity against HIV-1 activation (FLT, interferon 'Y, Ro 5-3335, and desferrioxamine) were titrated in OM-1 0.1 cells, and inhibition of RT activity and the percentage of remaining CD4+ cells were determined (Table 3 ). FLTwas markedly more potent than desferrioxamine in preventing the loss of CD4+ cells. lnterferon-v was effective in a dose-related fashion with more than 80% inhibition of RT at 100 U ml". In assays with FLT, desferrioxamine and interferon-v, inhibition was more pronounced when RT was used as the endpoint. This discrepancy probably reflects the sensitivity of CD4 surface expression to the production of intracellular gp-160 during activation of virus, resulting in rapid decline of these markers in OM-10.1 cells (Butera et al., 1991) . At 10 fLM, Ro 5-3335 inhibited HIV activation by 37% and 34% when measured by RT or CD4+ cells, respectively, suggesting a different mode of activity for this TAT-inhibitor when compared to FLT, desferrioxamine, or interferon
'Y-
In order to determine that the antiviral effects observed were not due to cytotoxicity, OM-1 0.1, and uninfected HL-60 cells were grown 24 and 48h under the same conditions as for the induction assays, and the toxicity was determined by trypan-blue exclusion. TNF-u was added 4 h after the cells were exposed to the various compounds in order to mimic the experimental conditions. As shown in Table 3 , FLT, interferon 'Y, Ro 5-3335, and desferrioxamine demonstrated no significant toxicity (:?:90% viability) at concentrations found to be effective at blocking viral activation.
Because FLT displayed antiviral activity unique among nucleoside analogues tested, the uptake and metabolism of FLT in HL-60 cells was studied over a24h period. In this r 
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effective against HIV-1 in acutely and chronically infected cells at non-toxic concentrations. An advantage of the OM-10.1 cell line is that compounds can be evaluated for their ability to bothjsnhance or suppress virus reactivation. A variety of natural products that have been claimed to inhibit HIV in chronically infected cells were evaluated (Table 1) . Compounds such as GLQ-223 (McGrath et aI., 1990) and interferons, other than IFN-'Y, were ineffective in the OM-1 0.1 system. Taxol, a potent anticancer agent that has been claimed to interfere with TNF-cr activation via a receptor down modulation (Ding et ei; 1990) , was also ineffective at non-toxic concentrations. The anti-HIV activity of IFN-cr, IFN-13 or IFN-'Yhas been demonstrated in vitro in acute and chronic infections (Hartshorn et aI., 1987; Pitha et sl., 1981) . However, in another study, INF-cr and -13 but not -'Y were shown to inhibit HIV (Yamamoto et aI., 1986) . Our studies demonstrates that only IFN-'Y was modestly effective in the OM-10.1 system. It is not clear why immune interferon had this unexpected property since it is known to upregulate TNF-receptor expression in certain cell lines (Lau et aI., 1991) . We have demonstrated a similar effect with IFN-'Y obtained from several sources (data not shown).
A variety of steroidal and non-steroidal anti-inflammatory agents, known to inhibit cyclooxygenase, were also ineffective. Thus, activation of prostaglandin synthesis is unlikely to be involved in the reactivation process. It is of interest that human nerve growth factor did not activate or affect TNF-cr induced virus reactivation in OM-10.1 cells either, suggesting that this growth factor could be used in combination with antiretroviral agents to reduce peripheral neuropathy that is commonly observed in AIDS patients undergoing therapy with 001, DOC, and D4T (Keilbaugh et aI., 1991) .
As expected, it appears from our studies that most nucleoside analogues, including AZT, inhibit only replicating virus and not activation of latent HIV. The exception is FLT, which was the only nucleoside analogue tested that inhibited HIV-reactivation at non-toxic concentrations. It is interesting that the anti-HIV-1 activity of AZT and DOC was reported to be completely abolished in infected Molt-4 cells treated with TNF-cr (Ito et aI., 1990) . TNF-cr did not alter the phosphorylation of AZT in these cells. Dextran sulphate, a non-nucleoside, retained its antiviral activity in this cell culture system even in the presence of 100 U rnr" of TNF-cr. It is conceivable that TNF-cr may also prevent the activity of AZT in OM-10.1 cells. It is widely assumed that the mechanism of antiviral activity of FLT is primarily due to its phosphorylation to FLT-TP which is known to inhibit HIV-1 RT and can also act as a chain terminator, preventing the elongation of new viral DNA (Matthes et a/., 1989; Schinazi et a/., 1991) . It is clear from our studies that FLT has an effect on viral reactivation in addition to the known effect of FLT-TP on RT. Other 3'-fluoro or 3'-azido experiment, the viability of the cell §',after 24 h exposure to 100 fLM FLTwas 80%. The corroentratlon of the cells exposed to FLT was measured at each time point, and the amount of phosphorylated FLT determined by anionexchange HPLC. Figure 2 indicated that substantial amounts of FLT-MP were rapidly produced intracellularly in these cells. More than 85% of the total intracellular radioactivity was found as this metabolite. The levels of FLT-TP increased over time. At 24h, 5.3% or 35.6pmoles 10-6 cells of FLT-TP were produced. After the first 6 h, the levels of FLT-DP plateaued at about 6 pmoles 10-6 cells. These results suggest that no unknown metabolite of FLT was produced in these cells. Studies on the regulation of HIV-1 transcriptional activation in latently infected human cells provide an understanding of the mechanisms of latency and reactivation and eventually may lead to methods for controlling AIDS. Many questions remain unanswered regarding latency and the state of the virus in infected cells (Stevenson et a/., 1990) . Whether a human gene is involved in suppressing HIV in these cells is not known (Drysdale and Pavlakis, 1991) . It is also unclear whether the inducing stimuli that activate HIV also activate other viruses (Miller, 1990) . The OM-10.1 system offers the possibility of identifying factors or antiviral chemotherapy will neccessitate the use of compounds that inhibit acute and chronic infection or reactivation of latent virus in combination (Schinazi, 1991) .
In this paper, we examined a variety of biologically important classes of compounds for their ability to interfere or enhance the HIV-1 reactivation process in OM-1 0.1 cells ( Table 1) . Some of these compounds are highly nucleosides evaluated were ineffective. These results emphasize the different biological properties of nucleoside analogues that are structurally related, and that inhibition of RT is probably not the only mechanism by which these nucleosides inhibit HIV-1 replication.
Other than the 3 phoshorylated forms of FLT, no new metabolite of FLT was noted during intracellular metabolic studies in HL-60 cells with radiolabelled compound. Similarly, no radioactive extracellular metabolite (other than FLT) was noted in supernatant from cultures treated with radiolabelled FLT (data not shown). FLT was also an effective inhibitor of HIV activation even when added up to 4h after TNF-activation (data not shown).
The trivalent iron chelator desferrioxamine was found to be a modest inhibitor of HIV-1 reactivation in the OM-10.1 system (fable 3). Desferrioxamine has been reported to inhibit HIV-1 replication in H9 cells (Tabor et aI., 1991) . Lazdins et al. (1991) reported that desferrioxamine was not a specific inhibitor of HIV-1 in acutely infected continuous cells lines, including H9 cells. However, the activity and selectivity of desferrioxamine in acutely infected human peripheral blood mononuclear (PBM) cells (EC so = 2.6-4.7 J.LM) was confirmed in our laboratory using the LAV strain of HIV-1 (Schinazi, 1992) . Although the mechanism of action is not known, DNA synthesis is inhibited through the inhibition of iron-dependent ribonucleotide reductase by desferrioxamine (Tabor et sl., 1991) ,and Kaplinsky and coworkers (1987) have used this drug to cause accumulation of HL-60 cells at the G 1/GO phase of the cell cycle and differentiation along the rnonocytlc-rnacrophaqe line. Other ribonucleotide reductase inhibitors such as hydroxyurea, Didox, and Trimidox had no effect on virus reactivation when tested up to 100 J.LM (fable 1), suggesting that inhibition of this enzyme is not crucial for viral reactivation. Recent studies indicate that desferrioxamine can only enter cells by pinocytosis and that once internalized it remains in the Iysosomes (Lloyd et aI., 1991) . Desferrioxamine has also been shown to inhibit blastogenesis of mouse lymphocytes with a median inhibitory concentration (IC so ) of 5 J.LM (Lipsky and Leitman, 1980) . In human PBM cells, the IC so was shown to be 34.8 J.LM using 3H-thymidine uptake method (unpublished results). Inhibition of blastogenesis could partly explain the effect of desferrioxamine on the activity of this compound in acutely infected cells and in OM-10.1 cells. An alternate hypothesis is that desferrioxamine inhibits haeme oxygenase, the 32 kD stress protein induced in cells treated with UVAradiation, H 202 , or sodium arsenate (theseagents are also known to activate HIV-1 in U1 cells) (Legrand-Pels et a/., 1990) .This possibility warrants further investigation. Of clinical interest is that desferrioxamine has been used effectively for the treatment of iron overload, and is claimed to be useful for the treatment of Alzheimer's disease, but long-term treatment with this drug is not known (McLachlan et et., 1991) .
Cells treated for 4h with the TAT-inhibitor Ro 5-3355 and then cultured in the presence of TNF-a produced a modest inhibition of RT and CD4 downmodulation. Ro 5-3335 has previously been shown to inhibit acute and chronic infections in vitro (Hsu et st., 1991) . Further studies are ongoing with this compound and other TAT-inhibitors as well as various proteinase inhibitors.
The intracellular pathways involved in HIV-1 activation from latency are becoming better defined. For example, protein kinase pathways have been demonstrated to be involved in virus reactivation. Hamamoto et a/. (1989) examined the effect of the potent protein kinase inhibitors staurosporine, H-7 and UCN-01 on 12-0-tetradecanoylphorbol-13-acetate (fPA) mediated CD4 downregulation and augmentation of HIV expression. Staurosporine was the only compound to demonstrate potent inhibition (Hamamoto et aI., 1989) . In the OM-10.1 system, various protein kinase inhibitors were effective in preventing reactivation of HIV-1 by TNF-a, but only at toxic concentrations (Butera et et., 1991) .
Both in OM-10.1 cells and in the U1 promonocytic model of latency, protein kinase pathways have been demonstrated to be involved in viral activation. The intracellular substrates for the activated kinases which ultimately result in HIV-1 expression are still uncertain. Several reports indicate that nuclear factor kappa B (NF-KB) is involved in activating HIV-1 LTR-directed transcription (Schreck et aI., 1991) : Furthermore, preformed NF-KBcan be released from its cytoplasmic inhibitor (I-KB) by a phosphorylation reaction (Ghosh et aI., 1990) . Therefore, I-KB appears a reasonable candidate for the action of protein kinases involved in HIV-1 activation transduction. However, HIV-1 regulatory proteins themselves are potential targets for phosphorylation and may be involved in signal transduction as well. N-Acetyl-L-cysteine (NAC), an antioxidant which counteracts the effects of reactive oxygen radicals in living cells, prevents the activation of NF-KB by hydrogen peroxide (Schreck et el., 1991) . High concentrations of NAC (15mM) have been reported to almost completely suppress HIV RNA accumulation and to inhibit HIV expression in acutely and chronically infected cells (Kalebic et a/., 1991; Roederer et aI., 1991) . It has been suggested that multiple steps of HIV expression can be affected by this class of reducing agent. HIV-1 can be activated by NF-KB and an upregulation of NF-KB activity results from TNF-a treatment of HL-60 cells. Therefore, it was of interest to determine if NAC could prevent HIV-1 induction in the OM-10.1 cells. Unfortunately, even at 3 mM, no activation or suppression of HIV was noted in our assay (cytotoxicity was apparent at 15mM; data not shown).
Several cellular models of latent infection have been described and used successfully to dissect HIV-1 activation.ln particular, the U1 promonocytic model has been studied extensively (Folks et aI., 1987) . However, as a r system for screening therapeutics for an ability to block activation, U1 cultures have several limitations. First, U1 cells contain two provirions which may be under very different regulatory mechanisms. Second, U1 cells respond to phorbol ester stimulation to a much greater extent than TNF-a, and require a stimulatory dose of TNF-a at least 5-fold higher than for OM-10.1 cells. These requirements result in somewhat artificial, non-physiologic induction of HIV-1 from latency. Furthermore, unlike U12 cells, OM-10.1 cells remain CD4+ until HIV-1 activation, providing a convenient and rapid means of analysis. It should be noted that activation by phorbol esters may not mimic activation in humans since these compounds, unlike TNF-a, are not natural products, The ability to monitor both CD4 and RT levels for evidence of viral induction also provides an assessment of drug toxicity. Cytostatic compounds will artificially reduce the supernatant RT levels due to a reduction in cell numbers; however, with OM-10.1, evidence of viral activation can be accurately monitored based on cell surface CD4 fluctuations.
There are no perfect models at thrs time for the study of virus reactivation. Even the conceptof latency with HIV is controversial. Ours is the first cell culture model which is relatively simple and reproducible in cells that appear normal (i.e., they remain >90% CD4+ until the virus is activated). The TNF-a activation of HIV in OM-10.1 cells is very reproducible and allows a quantitative assessment of virus load and CD4 depletion. The time needed to activate the production of infectious virus and depletion of CD4 receptors is highly predictable. The inter-and intra-variation (usually <10%) of replicate assays with the compounds described in this paper were consistent. This system allows us to rapidly evaluate a large number of compound using 24-well or even 48-well plates for inhibition and enhancement of HIV activation and will provide a useful tool for studying the mechanism of virus reactivation and its possible prevention.
In summary, of the various classes of compounds examined in this paper, only the nucleoside FLT, the cytokine IFN-"y, the TAT inhibitor Ro 5-3335, and the iron chelator desferrioxamine were found to have modest activity in the OM-10.1 cell system. The underlying mechanism of action of these compounds is not known. Combination studies are ongoing with these different antiviral agents to determine if they produce additive or synergistic antiviral interactions in OM-10.1 cells.
Materials and Experimental procedures

Materials
The compounds evaluated in OM-10.1 cells and their sources are listed in Table 1 . Stock solutions of the compounds were prepared by dissolving the compounds in water or DMSO. At the highest concentration of the compounds (usually 100 fLM), the Inhibition of HIV-1 activation 61 final concentration of DMSO was less than 0.5%. This concentration had no effect on the reactivation process. Radiolabelled [3H-5-MeJ-FLT was obtained from Moravek Biochemical Inc., Brea, CA.
Cell culture
The OM-10.1 cell line was maintained in RPMI-1640 basal medium containing 10% FCS, 2 mM glutamine and 1% Penn-Strep (GIBCO) at 37"C in a humidified atmosphere of 5% CO2/95% air. Each compound was evaluated by adding 10fLi of an appropriate dilution of drug to an individual 1ml culture containing 5 x 10 5 OM-10.1 cells in a 24-well plate which was then incubated for 4h. After this incubation, 20 U (1 ng) of TNF-a (Genzyme, Cambridge, MA) in 10 fLl was added to each well containing 1ml of medium and cells. As controls, 2 wells received TNF-a but no test compound, and 2 wells did not receive TNF-a ortest compound. Twenty-four hours after the addition ofTNF-a, the OM~10.1 cells were tested for CD4 expression and the supernatant was tested for HIV-1 RT activity at 36h after TNF-a activation. Compounds found to be effective in suppressing virus reactivation were retested to confirm their activity.
Determination of CD4 expression'
Cells were washed once in cold PBS and once in cold PBS containing 2% normal human AB+ serum, 0.2% sodium azide and 0.1% BSA (FACS buffer). Cell pellets were resuspended ih 75 fLl FACS buffer containing 5fLi of anti-CD4 mAb (OKT4, Ortho, Raritan, NJ) or, as a negative control, anti-CD8 mAb (OKT8, Ortho). After 1 h at 4°C, cells were washed twice with FACS buffer and resuspended in 100 fLl FACS buffer containing 1 fLl of goat-anti-mouse Ig-PE antibody, (Tago, Burlingame, CAl. After an additional 1 h at 4°C, cells were washed twice in FACS buffer and fixed at 4°C with PBS containing 1% paraformaldehyde in preparation for analysis on a Becton Dickinson FACScan system.
Quantitation of HIV-1 expression
HIV-1 expression was quantified by RT enzymatic activity as described previously (Butera et al., 1991) . Briefly, 5fLi of cell-free culture supernatant was added to 25 fLl of RT mixture containing polyadenylate oligo(dT) (Pharmacia Fine Chemicals, Piscataway, NJ), MgCb and [a-32PJ-deoxy-TTP (Amersham Corporation, Arlington Heights, IL) in duplicate wells of aU-bottom 96-well plate and incubated at 37°C for 2 h. From this mixture 5 fLl was then spotted onto DE81 ion exchange chromatography paper (Wt\atman International, Maidstone, UK), air-dried, washed five times in 1.5x citrate buffer (225fLM NaCI/22.5 fLM sodium citrate, pH 7.0) and twice more with 95% ethanol. The paper spots were then dried and the remaining radioactivity was quantitated in a Beckman LS 7000 scintillation counter.
Cell cytotoxicity assays
Compounds found to be effective in the assay were also evaluated for their ability to inhibit proliferation of OM-10.1 and uninfected parental HL-60 cells. The compounds at various concentrations were incubated with the cells in 25 ern"flasks for 24h, after which TNF"a (20Uml-1 ) was added. At 48h, the cells were counted by a trypan exclusion method, as described previously (Schinazi et a/., 1990) .
FL T uptake and metabolism
HL-60 cells were suspended at a concentration 2 x 10 6cellsml-1 in complete medium containing 100 fLM FH)-FLT (specific activity 28.85mCimmol-1, 118 fLCimg-1, 1Ornqrnl") and incubated at 3rC in 5% CO 2/95% air. Cells were exposed to drug in duplicate cultures for 2, 6, 12, and 24 h. At each timepoint, 10ml suspension was removed and centrifuged. The supernatant was removed at stored at -70°C, and the cells were washed once with cold PBS and counted. Cell extraction was performed with 200 ul of cold 60% MeOH in water. After storage overnight at -70°C, the extraction was repeated twice for 30min each. After centrifugation, the supernatants were pooled and dried using speed vacuum (SpeedVac SC-100, Savant Instruments, Inc., NY). The residues were resuspended in 250 fLl of water, and aliquots of 100 fLl were analysed by HPLC using a Micromeretic 750 or Hewlett Packard 1050 instrument. A Partisil 10 SAX column (Whatman, Clifton, NJ) was used for separation, with a flow rate of 1rnlmln" '. The mobile phase and conditions were as follows: 15 min 12.5 fLM NaH2P04 and 100 mM NaOAc, pH = 6.6, followed by 20 min gradient to 100 mMNaH 2P04 and 800 mMNaOAc, pH = 6.6, and then isocratically for 25 min with the high salt concentration buffer. Compounds were detected at a UV wavelength of 262nm. The retention times for FLT, FLT-MP, FLT-DP and FLT-TP were 4. 5,9.8,29.5, and 40 .9 min respectively. Markers for the nucleotides were obtained by partial enzyme degradation of FLT-TP obtained from Dr. S. Lang (Americn Cyanamid Co., Pearl River, NY).
